Medullary Cancer of the Breast

2014 ◽  
pp. 287-289
Author(s):  
Radhakrishna Selvi
Keyword(s):  
1986 ◽  
Vol 25 (06) ◽  
pp. 227-231 ◽  
Author(s):  
Chr. Eilles ◽  
W. Spiegel ◽  
W. Becker ◽  
W. Börner ◽  
Chr. Reiners

The monoclonal anti-CEA F(ab’)2 fragment MAb BW 431/31, labelled with 123I or111 In, was used for immunoscintigraphy (IS) in 9 patients with medullary cancer of the thyroid (CCC). The results of 11 studies lead to the following conclusions: 1) When using radioiodine as a label for MAb in IS, potassium iodide is absolutely necessary to block the thyroid which is of special importance in patients with thyroid cancer; 2) Preinjection of “cold” MAb reduces the relatively high unspecific uptake (especially in bone marrow) of MAb BW 431/31, which is of special importance for the antibody labelled with 111 In; 3) IS with MAb BW 413/31 in patients with CCC and elevated serum CEA is positive only in cases with large secondaries; and 4) In patients with CCC and several manifestations of secondaries, only a single (large) metastasis may be apparent.


2022 ◽  
Vol 2 (1) ◽  
pp. 87-92
Author(s):  
RITA STEFANUCCI ◽  
DOMIZIANA SANTUCCI ◽  
SILVIA MARIA ROSSI ◽  
MATTEO SAMMARRA ◽  
ELIODORO FAIELLA ◽  
...  

Background: Secretory and medullary carcinomas of the breast are rare subtypes of infiltrating ductal carcinoma. The different histological behavior of medullary and secretory carcinomas is correlated with different imaging features on mammography, ultrasound, and magnetic resonance imaging. Case Report: We report the case of a Caucasian woman in which both subtypes of tumors were diagnosed in an 8-year time interval and evaluate, in antithesis, histopathological and imaging aspects of medullary and secretory carcinoma. Conclusion: To our knowledge, this is the first case reported in literature of secretory carcinoma with a complete imaging tumor evaluation in a patient with a previous contralateral medullary cancer.


1874 ◽  
Vol 90 (10) ◽  
pp. 232-235
Author(s):  
George Holmes Bixby
Keyword(s):  

The Lancet ◽  
1868 ◽  
Vol 92 (2340) ◽  
pp. 2-3
Author(s):  
Christopher Heath
Keyword(s):  

1995 ◽  
Vol 41 (2) ◽  
pp. 26-26
Author(s):  
P. S. Vetshev ◽  
G. A. Mel'nichenko ◽  
N. S. Kuznetsov ◽  
T. I. Romantsova ◽  
O. V. Rojk

In recent years, more and more attention is drawn to the study of multiple endocrine neoplasia (MEN) - neoplastic syndromes with lesions of two or more endocrine glands. The source of tumors are tissues with embryologically common neuroectodermal origin, belonging to the APUD system. To date, there are three well-defined types of MEN syndromes: MEN I, the most important components of which are tumors of the parathyroid glands (in 80% of cases), pituitary (75%) and pancreas (65%); MEN IIA-medullary thyroid carcinoma (97%), hyperparathyroidism (50%) and pheochromocytoma (30%); MEN II B – multiple neuromas of the mucous membranes (100%), medullary thyroid carcinoma (90%), marphanoid appearance (65%) and pheochromocytoma (45%). Descriptions of observations of Sipple's syndrome - a combination of pheochromocytoma and medullary thyroid cancer are fairly common in both domestic and foreign literature. It has been repeatedly emphasized that the syndrome is caused by the presence of an autosomal dominant gene with high penetrance. However, in our opinion, the collection of family history and the need to examine the relatives of patients is not always given due attention. In the analysis of a large number of observations of MEN II found that pheochromocytoma is diagnosed primarily only in 10% of patients, 50% - in the examination for medullary cancer and 40% - in the late stages of neoplasia.


2015 ◽  
Vol 53 (1) ◽  
pp. 19-25 ◽  
Author(s):  
Edyta Gurgul ◽  
Aldona Kasprzak ◽  
Agata Blaszczyk ◽  
Maciej Biczysko ◽  
Joanna Surdyk-Zasada ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document